[go: up one dir, main page]

WO2013019222A1 - Compositions et procédés de traitement du syndrome myélodysplasique - Google Patents

Compositions et procédés de traitement du syndrome myélodysplasique Download PDF

Info

Publication number
WO2013019222A1
WO2013019222A1 PCT/US2011/046319 US2011046319W WO2013019222A1 WO 2013019222 A1 WO2013019222 A1 WO 2013019222A1 US 2011046319 W US2011046319 W US 2011046319W WO 2013019222 A1 WO2013019222 A1 WO 2013019222A1
Authority
WO
WIPO (PCT)
Prior art keywords
ezatiostat
salt
administered
hydrochloride
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/046319
Other languages
English (en)
Inventor
Gail L. Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Priority to PCT/US2011/046319 priority Critical patent/WO2013019222A1/fr
Publication of WO2013019222A1 publication Critical patent/WO2013019222A1/fr
Priority to IL230729A priority patent/IL230729A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to compositions and methods for treating myelodysplasia syndrome.
  • MDS Myelodysplasia syndrome(s) refers to a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis (blood cell production) involving one or more cell lineages (red blood cells, white blood cells or platelets) and a variable risk of transformation to acute myeloid leukemia (AML). This syndrome becomes more common with age. It is estimated that MDS affects
  • Ezatiostat and its salts are disclosed in US Patent No. 5,763,570.
  • Ezatiostat has the IUPAC chemical name of ethyl (2S)-2-amino-5-[[(2R)-3-benzylsulfanyl-l-[[(7R)-2- ethoxy-2-oxo-l-phenylethyl]amino]-l-oxopropan-2-yl]amino]-5-oxopentanoate.
  • ezatiostat hydrochloride (USAN)
  • U.S. Patent Application No. 13/041,136 filed March 4, 2011, describes ansolvate and polymorphs of ezatiostat hydrochloride.
  • Ezatiostat hydrochloride has been evaluated for the treatment of MDS, in a Phase I-IIa study using a liposomal formulation (US Patent No.
  • this invention is directed to a method for treating MDS in a patient which method comprises administering to that patient a therapeutically effective amount of ezatiostat or a salt thereof equivalent to up to about 2 grams (g) per day of ezatiostat hydrochloride for at least 2 weeks.
  • the dosing of ezatiostat or a salt thereof is a therapeutically effective amount of up to about 1 gram ezatiostat hydrochloride (or equivalent) administered twice a day (b.i.d.).
  • ezatiostat or a salt thereof is administered orally.
  • the patient is treated with ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride for three weeks followed by a week interruption without ezatiostat treatment. After the fourth week, the regimen can be repeated as necessary.
  • the ezatiostat or a salt thereof is administered twice a day, for example in equal doses.
  • this invention is directed to use of a therapeutically effective amount of ezatiostat or a salt thereof for the preparation of a oral medicament for treating a myelodysplasia syndrome, said ezatiostat or a salt thereof is equivalent to up to about 2 grams of ezatiostat hydrochloride per day for at least 2 weeks.
  • the patient is treated continuously with a therapeutically effective amount of ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride preferably administered in divided doses twice a day. It is contemplated that in this embodiment, the therapeutically effective amount of ezatiostat or a salt thereof may be less than that when there is a week interruption in the treatment regimen.
  • ezatiostat or a salt thereof can be administered as a tablet formulation. Such a tablet formulation is disclosed in U.S. Patent Application No.
  • this invention is directed to a treatment regimen for treating MDS using ezatiostat or a salt thereof.
  • ezatiostat or a salt thereof.
  • the singular forms "a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.
  • reference to "a pharmaceutically acceptable excipient” includes a plurality of pharmaceutically acceptable excipients.
  • compositions and methods include the recited elements, but do not exclude others.
  • Consisting essentially of when used to define compositions and methods shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • Consisting of means excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.
  • treatment means any treatment of MDS in a patient which produces one or more of the following: • inhibiting the disease or condition, that is, arresting or suppressing the
  • the term "patient” refers to mammals and includes humans and non-human mammals.
  • a numerical designation e.g., temperature, time, amount, and concentration, including range, indicates approximations which may vary by ( + ) or ( - ) 15 %, 10 %, 5 % or 1 %.
  • therapeutically effective amount refers to the amount of ezatiostat or a salt thereof that is an amount sufficient to effect treatment, as defined herein, when administered to a subject in need of such treatment. In one embodiment, the
  • therapeutically effective amount will be ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride administered per day.
  • ezatiostat or a salt thereof is administered in an amount of 2 grams per day and, more preferably, is administered twice a day in equal 1 gram doses.
  • Such a therapeutically effective amount is particularly relevant when the treatment regimen is for 3 weeks of administration of ezatiostat or a salt thereof followed by a week of no administration of the drug.
  • therapeutically effective amounts used in continuous administration may be lower than the amounts used during a three week treatment cycle followed by a week of no administration.
  • this invention is directed to a method for treating MDS in a patient in need thereof which method comprises orally administering to that patient a therapeutically effective amount of ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride for at least 2 weeks.
  • the dosing of ezatiostat or a salt thereof is a therapeutically effective amount of up to about 1 gram ezatiostat hydrochloride (or equivalent) administered twice a day.
  • ezatiostat or a salt thereof is administered in 1 gram dosages twice a day for three weeks followed by an interruption of 1 week. After the interruption, the regimen can be repeated as necessary. This regimen may be referred to as the "three-week regimen.”
  • the patient is treated continuously with a therapeutically effective amount of ezatiostat or a salt thereof equivalent to up to about 2 grams per day of ezatiostat hydrochloride, preferably in two divided doses, for at least two weeks.
  • ezatiostat or a salt thereof can be administered so long as the patient is in need of and can tolerate such treatment. It is contemplated that in this embodiment, the therapeutically effective amount of ezatiostat or a salt thereof may be less than that when there is an interruption in the treatment regimen. This regimen may be referred to as the "continuous regimen.”
  • the treatment with ezatiostat or a salt thereof may involve one or a combination of two or more of the dosing regimens described herein.
  • the following are exemplifying dosing schedules of ezatiostat hydrochloride:
  • ezatiostat hydrochloride or equivalent of ezatiostat or another salt
  • Ezatiostat hydrochloride in the above dosings can be replaced with an equivalent amount (in terms of ezatiostat content) of ezatiostat itself or another salt of ezatiostat.
  • ezatiostat or a salt thereof can be delivered as a tablet.
  • Examples of such a tablet formulation are disclosed in U.S. Patent Application No. 13/075,116, filed March 29, 2011, titled "TABLET FORMULATION OF
  • the interval between the first and second doses be from about 6 to 14 hours and more preferably between abut 8 and 14 hours.
  • the median age was 72 years, with a patient population distribution of
  • IDS International Prognostic Scoring System
  • DMTI DNA methyltransferase inhibitors
  • HI-N Hematologic Improvement - Neutrophil
  • GI gastrointestinal
  • nausea 45%, 16%), diarrhea (25%), 7%>) and vomiting (30%>, 12%).
  • Grade 3 events were uncommon: nausea (1%), diarrhea (3%) and vomiting (2%).
  • Prior DMTI treatment was associated with an increased incidence of GI AEs.
  • Telintra® treatment may result in clinically significant hematologic improvement in patients with MDS and may offer an alternative to RBC transfusions. These results are consistent with levels of efficacy observed in prior studies with Telintra®, the first GST Pl-1 enzyme inhibitor tested in MDS patients.
  • the data show both administration of 2 grams of ezatiostat hydrochloride per day over a 3 week period and administration of 3 grams of ezatiostat hydrochloride per day over a 2 week period provided efficacy in treating MDS. Furthermore and unexpectedly, the data show that administration of 2 grams of drug per day over a 3 week period gave a duration of response of 46.1 weeks versus the 18.4 weeks when 3 grams of ezatiostat hydrochloride per day were administered over a 2 week period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des schémas de traitement spécifiques du syndrome myélodysplasique.
PCT/US2011/046319 2011-08-02 2011-08-02 Compositions et procédés de traitement du syndrome myélodysplasique Ceased WO2013019222A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2011/046319 WO2013019222A1 (fr) 2011-08-02 2011-08-02 Compositions et procédés de traitement du syndrome myélodysplasique
IL230729A IL230729A0 (en) 2011-08-02 2014-01-30 Preparations and methods for the treatment of myelodysplastic syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/046319 WO2013019222A1 (fr) 2011-08-02 2011-08-02 Compositions et procédés de traitement du syndrome myélodysplasique

Publications (1)

Publication Number Publication Date
WO2013019222A1 true WO2013019222A1 (fr) 2013-02-07

Family

ID=44630570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/046319 Ceased WO2013019222A1 (fr) 2011-08-02 2011-08-02 Compositions et procédés de traitement du syndrome myélodysplasique

Country Status (2)

Country Link
IL (1) IL230729A0 (fr)
WO (1) WO2013019222A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113611A (en) 1976-11-16 1978-09-12 Westinghouse Electric Corp. Magnetic pipe cleaner
US5763570A (en) 1987-10-13 1998-06-09 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7511611B2 (en) 2006-05-18 2009-03-31 Casella Waste Systems, Inc. Systems for and methods of asset management in a waste management service environment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113611A (en) 1976-11-16 1978-09-12 Westinghouse Electric Corp. Magnetic pipe cleaner
US5763570A (en) 1987-10-13 1998-06-09 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
US7029695B2 (en) 2001-07-10 2006-04-18 Telik, Inc. Therapeutic compositions containing glutathione analogs
US7511611B2 (en) 2006-05-18 2009-03-31 Casella Waste Systems, Inc. Systems for and methods of asset management in a waste management service environment

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANNUAL MEETING OF THE AMERICAN SOCIETY FOR HEMATOLOGY, 2005
ANNUAL MEETING OF THE AMERICAN SOCIETY FOR HEMATOLOGY, 2007
ANONYMOUS: "Phase 2 Study Comparing Two Dose Schedules of Telintra in Myelodysplastic Syndrome", INTERNET CITATION, pages 1 - 3, XP002651485, Retrieved from the Internet <URL:http://clinicaltrials.gov/ct2/show/NCT00700206?term=ezatiostat&rank=3> [retrieved on 20110719] *
ANONYMOUS: "Telik report phase II data on ezatiostat in MDS", INTERNET CITATION, 9 June 2010 (2010-06-09), pages 1, XP002651700, Retrieved from the Internet <URL:https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml _show_ficha_ref?p_ref_id=1513842> [retrieved on 20110720] *
QUDDUS ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 3, 23 April 2010 (2010-04-23), pages 16
RAZA AZRA ET AL: "Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 116, no. 21, 1 November 2010 (2010-11-01), pages 1198, XP009150424, ISSN: 0006-4971 *
RAZA ET AL., BLOOD, vol. 113, 27 April 2009 (2009-04-27), pages 6533 - 6540
RAZA ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 2, 13 May 2009 (2009-05-13), pages 20

Also Published As

Publication number Publication date
IL230729A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
TW201210593A (en) Compositions and methods for treating centrally mediated nausea and vomiting
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
JP7489397B2 (ja) Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用
AU2011202637A1 (en) Composition and methods for treating myelodysplastic syndrome
EP4110326B1 (fr) Combinaison comprenant de l&#39;alpélisib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique
JP2008514721A (ja) 治療方法
WO2013019222A1 (fr) Compositions et procédés de traitement du syndrome myélodysplasique
HK1162149A (en) Compositions for use in treating myelodysplastic syndrome
CN107519176A (zh) 防治运动病、梅尼埃病的药物及莫扎伐普坦的医药用途
MX2011009301A (es) Composiciones y metodos para tratar sindrome mielodisplasico.
TW201306831A (zh) 用於治療骨髓發育不良症候群的組成物及方法
WO2013019220A1 (fr) Compositions et procédés de traitement du syndrome myélodysplasique
KR20130020944A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
CN104906501A (zh) 治疗银屑病的中药组分组合物
KR20130020945A (ko) 골수이형성 증후군을 치료하기 위한 조성물 및 방법
Hussar New Drugs 2021, Part 2
MX2011009302A (es) Composiciones y métodos para el tratamiento de sindrome mielodisplasico.
HK1162310A (en) Compositions for use in treating myelodysplastic syndrome
TW201306832A (zh) 用於治療骨髓發育不良症候群的組成物及方法
KR20150063040A (ko) 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제
CN103301115A (zh) 一种治疗癫痫的药物组合物
CA2742054A1 (fr) Composition et methodes destinees au traitement du syndrome myelodysplasique
HK40057612A (en) Application of chidamide in combination with r-chop, and drug combination
CN108478581A (zh) 防治运动病、梅尼埃病的药物及托伐普坦的医药用途
BRPI1103978A2 (pt) composiÇÕes e mÉtodos para tratar sÍndorme mielodisplÁsica

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11746370

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11746370

Country of ref document: EP

Kind code of ref document: A1